Parallume Inc

Parallume Inc. is a biotechnology company aimed at revolutionizing the field of molecular diagnostic testing for life-science researchers in academic, industrial, and clinical settings. We strive to provide reliable, cost-effective, and versatile multiplex assays for biomedical research, disease diagnosis and whole health monitoring. Parallume Inc. currently offers a novel multiplex technology platform that includes: 1) a patent-protected, bead-based optical encoding material (“Parallume” TM), 2) a series of bead localization substrates for ease of handling, and 3) a line of multiplex assay reader system (“MARS” TM) imaging instruments for both laboratory and portable, low-resource applications. The Parallume technology platform provides an unprecedented level of plex sizes and supports a numerous biological assay formats, including but not limited to real-time PCR, ELISA, and cell capture/isolation. Parallume Inc. is currently seeking opportunities for investment and/or partnership to allow for further development and commercialization of this technology. Please visit our website to learn more about our technology! Also, please check out our publication, entitled "Multiplex Flow Assays", about our multiplex lateral flow assay (LFA) platform!